TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04999384: First in Human, Dose Escalation Study of AN4005

Sponsor: Adlai Nortye Biopharma Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 31 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,036,728

Rescue Site Savings

+$691,152

Unlock Full NCT04999384 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04999384 Rescue Dossier →